Page last updated: 2024-11-05

mevalonolactone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

mevalonolactone: RN given refers to unlabeled cpd without isomeric designation; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

mevalonolactone : A racemate comprising equimolar amounts of (R)-mevalonolactone and (S)-mevalonolactone. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID6419891
CHEMBL ID1401520
CHEBI ID67849
SCHEMBL ID879
MeSH IDM0064561

Synonyms (46)

Synonym
mevalonic acid lactone
mevalonic-d, l acid lactone
PRESTWICK_97
NCGC00016531-01
cas-674-26-0
PRESTWICK2_000750
SPBIO_002679
PRESTWICK0_000750
PRESTWICK1_000750
mevalonolactone
(4r)-4-hydroxy-4-methyloxan-2-one
HMS1570E22
r-mevalonolactone, (-)-
CHEBI:67849 ,
adeka mevalonolactone
2h-pyran-2-one, tetrahydro-4-hydroxy-4-methyl-, (r)-
(3r)-mevalonolactone
2h-pyran-2-one, tetrahydro-4-hydroxy-4-methyl-, (4r)-
unii-661x270z3l
(-)-mevalonolactone
mevalonolactone, (-)-
661x270z3l ,
(-)-(r)-mevalonolactone
(-)-(r)-mevalonic acid lactone
19115-49-2
(r)-(-)-mevalonolactone
d-mevalonic acid lactone
mevalonolactone [inci]
AKOS017343730
SCHEMBL879
(r)-4-hydroxy-4-methyltetrahydro-2h-pyran-2-one
(r)-(-)-3-hydroxy-3-methyl-5-pentanolide
M-6701
CHEMBL1401520
(r)-(-)-mevalonolactone, >=90.0% (gc)
mfcd01074894
r-mevalonolactone
JYVXNLLUYHCIIH-ZCFIWIBFSA-N
(r)-3-hydroxy-3-methyl-5-pentanolide
Q27136326
r)-(-)-3-hydroxy-3-methyl-5-pentanolide
d,l-mevalonic-acid-lactone
SB47779
r(-)mevalonolactone
d-mevalonolactone
A937707

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" These results indicate that muscle cells may be particularly susceptible to a statin-induced suppression of essential antioxidant selenoproteins, which provides an explanation for the disposition of these drugs to evoke adverse muscular side-effects."( Prooxidative toxicity and selenoprotein suppression by cerivastatin in muscle cells.
Fuhrmeister, J; Kromer, A; Moosmann, B; Tews, M, 2012
)
0.38

Dosage Studied

ExcerptRelevanceReference
" The effects of cholestyramine rapidly disappeared when it was withdrawn from the diet, while the effects of gemfibrozil persisted after dosage was stopped."( Some comparative effects of gemfibrozil, clofibrate, bezafibrate, cholestyramine and compactin on sterol metabolism in rats.
Maxwell, RE; Nawrocki, JW; Uhlendorf, PD, 1983
)
0.27
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
fungal metaboliteAny eukaryotic metabolite produced during a metabolic reaction in fungi, the kingdom that includes microorganisms such as the yeasts and moulds.
plant metaboliteAny eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
4-hydroxy-4-methyloxan-2-oneA member of the class of 2-pyranones that is tetrahydro-2H-pyran-2-one substituted by a methyl and hydroxy group at position 4.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (4)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
USP1 protein, partialHomo sapiens (human)Potency39.81070.031637.5844354.8130AID504865
cytochrome P450 2C9 precursorHomo sapiens (human)Potency12.58930.00636.904339.8107AID883
lamin isoform A-delta10Homo sapiens (human)Potency14.12540.891312.067628.1838AID1487
Histamine H2 receptorCavia porcellus (domestic guinea pig)Potency12.58930.00638.235039.8107AID883
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (3)

Assay IDTitleYearJournalArticle
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (184)

TimeframeStudies, This Drug (%)All Drugs %
pre-199061 (33.15)18.7374
1990's69 (37.50)18.2507
2000's25 (13.59)29.6817
2010's25 (13.59)24.3611
2020's4 (2.17)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (0.54%)5.53%
Reviews2 (1.08%)6.00%
Case Studies1 (0.54%)4.05%
Observational0 (0.00%)0.25%
Other181 (97.84%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]